IDH1 and central nervous system cancer: Another multicenter phase 1 study evaluated BAY1436032 in 29 patients with recurrent IDH-1 mutant gliomas.146 There was a complete response in one grade 3 astrocytoma patient, and a partial response in a grade 3 astrocytoma and 2 grade 3 oligodendroglioma patients.